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Abstract
Background—Transmitted drug resistance (TDR) is increasing in some areas of Africa.
Detection of TDR may predict virologic failure of first-line non-nucleoside reverse-transcriptase
inhibitor (NNRTI)-based antiretroviral therapy (ART). We evaluated the utility of a relatively
inexpensive oligonucleotide ligation assay (OLA) to detect clinically relevant TDR at time of
ART initiation.
Methods—Pre-ART plasmas from ART-naive Kenyans initiating an NNRTI-based fixed-dose
combination ART in a randomized adherence trial conducted in 2006 were retrospectively
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analyzed by OLA for mutations conferring resistance to NNRTI (K103N, Y181C, and G190A)
and lamivudine (M184V). Post-ART plasmas were analyzed for virologic failure (≥1,000
copies/mL) at 6 month intervals over 18-month follow-up. Pre-ART plasmas of those with
virologic failure were evaluated for drug resistance by consensus and 454-pyrosequencing.
Results—Among 386 participants, TDR was detected by OLA in 3.89% [95% Confidence
Interval (CI), 2.19-6.33], and was associated with a 10-fold higher rate of virologic failure [Hazard
Ratio (HR), 10.39; 95% CI, 3.23-32.41; p<0.001) compared to those without TDR. OLA detected
24 TDR mutations (K103N, n=13; Y181C, n=5; G190A, n=3; M184V, n=3) in 15 subjects
(NNRTI, n=15; 3TC, n=3). Among 51 participants who developed virologic failure, consensus
sequencing did not detect additional TDR mutations conferring high-level resistance, and
pyrosequencing only detected additional mutations at frequencies <2%. Mutant frequencies <2%
at ART initiation were significantly less likely to be found at the time of virologic failure
compared to frequencies ≥2% (22% vs. 63%; p<0.001).
Conclusions—Detection of TDR by a point mutation assay may prevent use of sub-optimal
ART.
Keywords
transmitted drug resistance; oligonucleotide ligation assay; HIV; Kenya; antiretroviral therapy
Introduction
Access to antiretroviral therapy (ART) has substantially increased in many areas of sub-
Saharan Africa over the last decade,1,2 yet patients are failing ART and HIV resistance to
some antiretroviral medications is increasing.3,4 As a result, ART-naïve individuals are
becoming infected with transmitted drug resistant virus (TDR) and failing first-line ART
based on non-nucleoside reverse transcriptase inhibitors (NNRTI).5 Public health officials in
Africa will need to decide when resistance testing prior to ART initiation is warranted to
prevent early treatment failure.6
HIV resistance testing by consensus sequencing or newer ultra-deep sequencing methods are
costly and require equipment and technical capacity beyond what is accessible at many
African HIV clinics. An oligonucleotide ligation assay (OLA), which is relatively
inexpensive compared to conventional sequencing, has been shown to detect HIV resistance
selected by single-dose nevirapine that is associated with virologic failure.7 It is not known
whether the implementation of OLA prior to ART initiation might decrease virologic failure
in Africa.
We designed a retrospective study to describe the prevalence of TDR in Nairobi, Kenya in
2006 and to determine whether OLA-detected TDR was associated with virologic failure. In
addition, we examined whether low-frequency mutations or mutations at codons not
evaluated by OLA contributed to virologic failure.
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Methods
Setting
A retrospective analysis of TDR using data and specimens collected from participants in a
randomized controlled trial on adherence in Nairobi, Kenya was conducted. The design and
methods of the adherence study are described elsewhere.8 In brief, 400 ART-naïve
individuals eligible to start ART at the Coptic Hope Center for Infectious Diseases were
enrolled in 2006 and equally randomized to: adherence counseling; alarm device; combined
adherence counseling and alarm device; or a control group that received neither
intervention.8,9 First-line ART regimen was initiated with a fixed-dose combination of
nevirapine (NVP), lamivudine (3TC) and stavudine (d4T). The trial demonstrated that
adherence counseling significantly increased adherence and reduced virologic failure while
alarm device had no effect.8
Study design
Sociodemographic information, adherence data, and blood samples from the adherence trial
were used in this analysis. After initiating ART, participants had monthly pill counts and
ART refills. Plasma HIV RNA levels (Gen-Probe, San Diego, CA, USA) and CD4 counts
(FACScan, Becton Dickinson, Franklin Lanes, NJ, USA) were determined at baseline prior
to ART initiation, and at 6, 12, and 18 months of ART. Virologic failure was defined as
plasma HIV RNA copies ≥1,000 copies/mL at least 4 months after ART initiation.10
To measure TDR, plasma collected at baseline from all participants was evaluated for
NNRTI and 3TC drug resistance mutations by OLA. Participants who experienced virologic
failure were evaluated for additional mutations at baseline by consensus sequencing and
454- pyrosequencing of their pre-ART plasma specimen. Plasma samples at the time of
virologic failure were analyzed by OLA and consensus sequencing.
Nucleic acid extraction and PCR amplification of HIV pol
RNA was extracted from 0.5-1mL of pre-ART plasma (NucliSENS miniMAG, bioMérieux,
Durham, NC, USA). After reverse transcription (Superscript III, Invitrogen, Grand Island,
NY, USA) with random hexamers, HIV pol spanning codons 1-239 of RT was amplified
(MyTaq DNA Polymerase, Bioline USA Inc, Taunton, MA, USA) by nested polymerase
chain reaction (PCR) (1st round primers; forward:
GARAGACAGGCTAATTTTTTAGGGA, and reverse:
AAYTTCTGTATATCATTGACAGTCCA; 2nd round primers forward:
CAAATCACTCTTTGGCARCGACC and reverse: CAYTTGTCAGGATGGAGTTCATA).
Oligonucleotide ligation assay (OLA)
Amplicons from baseline and virologic failure were tested by an OLA for point mutations
conferring resistance to NNRTI (K103N, Y181C and G190A) and 3TC (M184V).11,12 The
OLA used probes optimized for subtypes A, D and C prevalent in Kenya. Standards of
plasmids mixed to contain 0%, 2%, 5%, 10%, 25%, 50%, 75% or 100% mutant in a wild-
type background were included in each assay plate, and comparisons of the optical densities
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of each specimen to those of the standards was used to quantify the proportion of mutant in
the HIV population.13
Dideoxy-nucleotide consensus sequencing and parallel 454-pyrosequencing
Amplicons from individuals with virologic failure underwent dideoxy-nucleotide consensus
sequencing to identify mutations both at baseline and at the first time point when virologic
failure was detected (GenBank sequence accession numbers: KF544089-KF544288,
KJ395348 and KJ395349).14,15 Massive parallel 454-pyrosequencing was performed on
baseline plasma samples of individuals with virologic failure and/or OLA-detected
mutations. After reverse transcription of plasma HIV RNA as described above, the cDNA
was quantified by HIV LTR real-time PCR.16 Approximately 1,000 templates of amplifiable
HIV were submitted to a median of three nested PCR (range, 1 to 20 reactions) with
subsequent pooling of amplicon. First round PCR used the primers described above and
FastStart High Fidelity PCR System (Roche Diagnostics, Mannheim, Germany).
Subsequently, two regions of HIV reverse transcriptase were amplified in separate second
round PCR with 454-barcoded-fusion primers (454 Life Sciences, Roche Diagnostics
Corporation, Branford, CT, USA), with 14 discrete multiplex identifiers (MID) or barcodes:
Amplicon 1 (RT codons 21-134)
Forward: CGTATCGCCTCCCTCGCGCCATCAG-
MIDGTTAAACAGTGGCCATTGACAGA
Reverse: CTATGCGCCTTGCCAGCCCGCTCAG-
MIDACTAGGTATGGTGAATGCAGTATA
Amplicon 2 (RT codons 150-242)
Forward: CGTATCGCCTCCCTCGCGCCATCAG-
MIDCACAGGGATGGAAAGGATCAC
Reverse: CTATGCGCCTTGCCAGCCCGCTCAG-
MIDCTGGACTGTCCATYTGTCAGGATG
Amplicons were visualized on agarose gels, purified using a High Pure PCR Product
Purification Kit (Roche Applied Science, Mannheim, Germany), and quantified using a
Quant-iT PicoGreen dsDNA Reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA).
Pools containing barcoded amplicons from 14 subjects, diluted to 1x107 molecules/μL,
underwent emulsion PCR and 454-sequencing using a 2-region gasket and the GS FLX
Titanium System per manufacturer's instructions (454 Life Sciences, Roche Diagnostics
Corporation, Branford, CT, USA).
The output was processed through a pipeline aligning sequences to a subtype-specific
consensus reference.17 Nucleotide frequencies at each position were calculated in forward,
reverse and overall reads to determine the frequency of mutants at codons conferring
resistance to NRTI and NNRTI as defined in the Stanford Database.14
Chung et al. Page 4
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Errors introduced by PCR and 454-sequencing were estimated by including amplicon of an
HIV-1 subtype A plasmid in each 454-sequencing plate. A control for errors in reverse
transcription was not included. The limit of mutant quantification was estimated based on
the number of HIV templates from each specimen submitted to the assay and the error rate
observed across 454-sequencing of the plasmid. Testing of a median of 1,000 (range
275-1,300) HIV templates per specimen by pyrosequencing and an average substitution
error rate of 0.06 +/− 0.01% SD observed in the plasmid control set the limit of mutant
detection at >0.1%.
Statistical methods
Wilcoxon rank sum and Fisher's exact tests were used to compare continuous and
categorical characteristics between those with and without TDR. Among those who initiated
ART, time to virologic failure was estimated using Kaplan-Meier (KM) analysis and groups
with and without TDR were compared using a log-rank test. Participants were censored if
they died or were lost to follow-up before the 18-month study endpoint.
A discrete time Cox proportional hazards regression model assessed differences in rates of
virologic failure. A preliminary model included TDR and randomization assignment.
Adjusted models also included baseline characteristics associated with TDR and virologic
failure, as well as age, employment status, baseline viral load, randomization assignment,
and adherence. Adherence was examined as a time-varying covariate as average adherence
in the prior 6 months.
Mutant frequency (<2% versus ≥2%) detected by pyrosequencing at baseline was assessed
for subsequent detection at viral failure by consensus sequencing using generalized
estimating equations (GEE) models with binomially-distributed errors, log link, and
exchangeable correlation matrix with robust errors. Among the subjects with virologic
failure, linear regression was used to assess time to viral failure between no (0%), “very
low” (>0% to <2% frequency), and “low-high” (≥2%) levels of mutations by
pyrosequencing. Stata SE v12 (Statacorp, College Station, TX, USA) was used in all
analyses; significance tests were two-sided, with alpha=0.05.
Ethical review
The study protocol was reviewed and approved by the institutional review boards at the
University of Washington (Seattle, WA, USA), Seattle Children's Hospital (Seattle, WA,
USA), and Kenyatta National Hospital (Nairobi, Kenya).
Results
Study population
Of 1,096 adults eligible to initiate ART at the Hope Center in 2006, 437 qualified for the
study and 400 were enrolled (Figure 1). Of the 400 enrollees, 386 had baseline pre-ART
plasma samples tested by OLA and 356 participants initiated ART and were assessed for
virologic failure. Prior to initiating ART, 22 participants were lost to follow-up and 8 died.
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A total of 307 participants (86%) completed 18 months of study follow-up. Between ART
initiation and the 18-month endpoint, 21 participants were lost to follow-up and 28 died.
Transmitted drug resistance and virologic failure
Among the 386 participants evaluated at baseline, 15 had one or more mutations detected by
OLA for a TDR prevalence of 3.89% [95% Confidence Interval (CI), 2.19-6.33]. The
median age among those with TDR was 37 years [Interquartile Range (IQR), 32-43], 60%
were female, 47% were married, and the median CD4 count was 100 cells/mm3 (IQR,
23-155) (Table 1). Compared to those without TDR, those with TDR were significantly
more likely to have had more lifetime sexual partners (median, 7 vs. 4; p=0.004), never
attended school (13% vs. 2%; p=0.044), and been casual laborers (33% vs. 13%; p=0.045).
CD4 count, plasma HIV-1 RNA, and randomization assignment did not differ between those
with and without TDR.
Among the 356 participants who initiated ART, 13 (3.65%) had TDR detected by OLA and
51 (14.3%) experienced virologic failure. Overall, the cumulative probability of virologic
failure at 18 months was 0.16 (95% CI, 0.12-0.21). The cumulative probability of virologic
failure among those with TDR was significantly higher (0.70; 95% CI, 0.42-0.93) compared
to those without TDR (0.14; 95% CI, 0.11-0.19) (Figure 2). Characteristics associated with
TDR in this subset were similar to those in the overall cohort. Those with TDR experienced
virologic failure at a rate 7.99 times (95% CI, 2.95-21.64; p<0.001) higher than those who
did not have TDR. In a model adjusting for age, employment status, baseline viral load,
adherence, and randomization assignment, the risk of virologic failure associated with TDR
was 10.39 (95% CI, 3.23-32.41; p<0.001).
Detection of baseline mutations by OLA
OLA, sensitive to a mutant frequency of 2%, detected 24 mutations in 15 participants at
baseline. These 15 had mutations associated with resistance to NNRTI and 3 also had
mutations associated with resistance to 3TC (Figure 3). The median mutant frequency in
each subject's viral population was 67% (range, 2%-100%).
Of the 15 participants who had mutations detected by OLA at baseline, virologic outcome
could not be ascertained for 5 participants; 3 died and 2 were lost before viral load was
measured. Of these 5 participants, 3 participants had a single mutation (K103N), 1
participant had 2 mutations (K013N and M184V), and 1 participant had 3 mutations
(K103N, Y181C, and G190A). Among the 10 with virologic outcome, 7 experienced
virologic failure: 3 of these participants had single mutations (K103N, n=2; Y181C, n=1); 2
participants had 2 mutations (K103N and G190A, n=1; Y181C and G190A, n=1); and 2
participants had 3 mutations (K103N, M184V, and Y181C). The median mutant viral load
in the pre-ART specimen of those who failed was 536,167 copies/mL (range, 12,976 –
2,128,896 copies/mL). Three participants with mutations detected by OLA at baseline did
not experience virologic failure after 18 months on ART and each had only a single
mutation (K103N); their mutant viral loads were 112,316, 642,240, and 585,469 copies/
mL.18
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Among the 7 participants who had mutations detected by OLA at baseline and experienced
virologic failure, all failed by month 6 (the first time point evaluated after ART initiation)
and 6 of the 7 had adherence ≥95%.
Detection of baseline mutations among virologic failures by consensus and
pyrosequencing
Of the 51 participants who experienced virologic failure, consensus sequencing detected 23
mutations in 10 participants and pyrosequencing detected 56 mutations in 24 participants at
baseline (Figure 3). Consensus sequencing confirmed baseline mutations in 6 of the 7
participants identified by OLA, and detected baseline mutations at sites associated with
“potential low-level resistance” to didanosine and abacavir or “low-level resistance” to
zidovudine and stavudine in 4 additional participants at codons not evaluated by OLA
(T215T/I, n=1; T69S, n=1; T69T/N, n=2) (hivdb.stanford.edu).
In addition to the 7 participants who had mutations identified by OLA, pyrosequencing
detected 17 additional participants with either very low (<2%) frequency mutations at the
codons tested by OLA (M184V, K103N, Y181C, G190A), or mutations (frequencies
0.1%-100%) in other codons conferring drug-resistance. Eleven individuals had mutations at
the OLA codons, all at frequencies <2%. The remaining 6 individuals had mutations at non-
OLA codons, all at frequencies <2%, except for 3 individuals: one with L210W detected at a
frequency of 5.9%, and two with T69N detected; one at a frequency of 22.5% and the
second at 25.0% (Figure 3).
Detection of baseline mutations at virologic failure
Of the 13 mutations detected in 7 participants by OLA at baseline, OLA detected 11 (85%)
and consensus sequencing detected 10 (77%) at the time of virologic failure. Two mutations
were detected by OLA at baseline but not at failure. In one participant, K103N at a
frequency of 5% co-existed with G190A; only the latter was detected at failure along with
Y181C and M184V. In another, Y181C was detected at baseline with additional mutations,
and at failure it had shifted to Y181V (Figure 3). Of the mutations classified as “potential
low-level resistance” or “low-level resistance” in the Stanford HIV Drug Resistance
Database (hivdb.stanford.edu), none were detected by consensus sequencing at virologic
failure.
Mutant variants detected in the pre-ART plasma at a frequency of <2% by pyrosequencing
were significantly less likely than those >2% frequency to be found by consensus
sequencing at the time of virologic failure. Of the 32 mutations detected by pyrosequencing
at baseline at frequency <2%, 7 (22%) were detected by consensus sequencing at the time of
virologic failure. Of the 24 mutations at frequency ≥2%, significantly more, 15 (63%), were
found at virologic failure (63% vs. 22%; p<0.001). This was also true when restricted to
codons evaluated by OLA (K103N, Y181C, G190A, and M184V). Among the 13 mutations
detected in “OLA codons” by pyrosequencing (and OLA) at frequency ≥2%, 10 (77%) were
detected by consensus sequencing at virologic failure compared to 5/14 (36%) at baseline
frequencies <2% (77% vs. 36%; p=0.049).
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Baseline mutant frequency and time to virologic failure
When examining OLA codons (K103N, Y181C, G190A, and M184V), the mean time to
virologic failure was significantly earlier among participants with baseline mutation
frequencies ≥2% by pyrosequencing compared to those with minority mutations (>0% to
<2%) (p=0.002) or no mutations (0%) (p=0.008) (Figure 4). In an analysis adjusting for age,
employment status, baseline viral load, adherence, and randomization assignment,
participants with mutant frequencies ≥2% experienced virologic failure 9.6 months earlier
compared to those with mutational frequencies between 0-2% (p=0.001) and 7.0 months
earlier compared to those with no mutations (p=0.004). There was no significant difference
in time to virologic failure between participants with resistance mutations present at
frequencies <2% compared to those with no mutations detected (p=0.194).
Discussion
In this analysis of 386 ART-naïve adults initiating ART in Nairobi, Kenya in 2006, we
found a TDR prevalence of 3.9%. TDR was determined using OLA that detected mutations
conferring high-level resistance to NNRTI and 3TC and was significantly associated with
virologic failure in this study. Those with TDR detected by OLA at one or multiple codons
(M184V, K103N, Y181C, and G190A) were 10 times more likely to experience virologic
failure than those without TDR. This evidence suggests that OLA performed prior to ART
initiation may guide antiretroviral prescribing practices to reduce rates of virologic failure.
The detection of TDR by this study in Nairobi, Kenya is consistent with increased
prevalence of antiretroviral resistance found in many resource-limited settings since the
widespread rollout of ART.3 To our knowledge, this study is the largest single site cohort
study of TDR detected among ART-naïve patients in East Africa. While the prevalence of
3.9% is less than 13.2% found among 68 Kenyans in Mombasa in 2009-10,19 7.5% among
53 in Nairobi in 2005,20 and 4.5% among 200 in Nairobi in 2008-9,21 it is greater than 1.1%
found among 182 Kenyans in Kilifi in 2008-10 and 3.1% among 76 across Kilifi, Nairobi,
and Mtwapa in 2006-9.22,23 In relation to these figures, the study's TDR prevalence is low
given the clinic's urban setting where ART coverage is relatively high. This may be due to
enrollment of only ART-naïve adults, examination of antiretroviral resistance at only 4
codons, and testing of specimens from 2006. It is expected that TDR prevalence will
continue to increase paralleling expansion of ART and evolving recommendations for earlier
initiation of treatment.24
The association between the detection of TDR and virologic failure is not new and has been
noted in both resource-rich and constrained settings.25-27 However, detection of TDR by
OLA, a point mutation resistance test, is novel. Inexpensive antiretroviral resistance testing
is needed in resource-limited settings, where most HIV patients cannot afford resistance
testing by consensus sequencing. OLA may be as much as 10-20 times less expensive than
consensus sequencing, and has been successfully implemented by laboratories in resource-
limited countries.12,28
Consensus sequencing and pyrosequencing at baseline did not appear to contribute more
information than OLA. Among those who experienced virologic failure, consensus
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sequencing did not detect additional subjects with pre-ART mutations associated with “high-
level resistance” beyond those identified by OLA testing (hivdb.stanford.edu). In addition,
the baseline mutants detected by consensus sequencing were not selected at virologic failure,
and suggests that these mutations may not have been clinically relevant in these subjects.
These data suggest that the codons tested by OLA were appropriate for this setting and time
period. Baseline mutations detected by pyrosequencing but not by OLA were primarily at
low frequencies (<2%) in participants’ viral populations, and were significantly less likely to
be selected at the time of virologic failure compared to those at a frequency ≥2%, which
were detectable by OLA. Given this finding as well as the shorter time to virologic failure
among those with mutant frequencies ≥2%, it appears that baseline mutations at low
frequencies <2% did not significantly contribute to virologic failure.
Weaknesses in this study include the limited number of samples tested by consensus
sequencing and pyrosequencing due to cost constraints. Although consensus sequencing was
not performed on all samples, detection of TDR by consensus sequencing probably would
have been just as predictive of virologic failure as OLA. Although the prevalence of TDR
was reported, the study is likely to have underestimated the actual prevalence, as a
comprehensive survey of all drug resistance codons was not performed since our primary
focus was to evaluate the utility of the OLA to predict virologic failure. Based on consensus
sequencing and pyrosequencing, OLA did not appear to miss the detection of mutations
associated with virologic failure. However, additional codons will be needed to screen for
TDR by OLA when antiretroviral regimens change within a community. Setting the limit of
mutant detection by pyrosequencing at >0.1% may be considered too low. While the 0.1%
estimate accounts for errors introduced by PCR and pyrosequencing, it does not account for
those introduced by reverse transcription. We chose to report the detection of mutations
detected above the error rate of our plasmid controls to allow the reader to compare
detection of mutations around the cutoff of OLA. Samples collected at 6-month intervals
may not have captured the exact time of virologic failure, and among participants with poor
adherence to antiretrovirals, the absence of selective pressure may have allowed resistance
mutations to be outcompeted by wild type viruses with greater replication capacity.
Additionally, our testing of pre-ART plasma may not have accurately measured the rate of
TDR in this cohort. It is possible that HIV infection was founded by drug-resistant variants
in some participants, but in the time interval between acute infection and collection of the
pre-ART specimen these mutants could have reverted to wild type variants.
The increasing rate of TDR observed in Africa could threaten efficacy of first-line ART.
Cost-effective strategies to contain drug-resistant HIV are needed for resource-poor
countries. This study suggests that pre-ART testing for HIV drug resistance with a point
mutation assay, which is less expensive than conventional sequencing, may be a viable
strategy to help preserve the efficacy of first-line ART. Among those with >95% adherence,
detection of TDR by OLA at ART initiation and subsequent regimen modification would
have averted 6/13 (46%) virologic failures at 6 months follow-up (data not shown). Further
development of simple, inexpensive assays to test for multiple drug-resistance mutations
appears warranted, as do feasibility and cost-effectiveness studies of these assays in low-
resource communities.
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Figure 1.
Trial Profile
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Figure 2.
Kaplan-Meier curve of time to virologic failure between those with presumed transmitted
drug resistance (TDR) detected in codons M184V, K103N, Y181C, and/or G190A by
oligonucleotide ligation assay (OLA) (dashed line) and those without TDR by OLA (solid
line).
Note: The number of participants at risk at each time point is listed and the number
experiencing virologic failure is in parentheses.
Chung et al. Page 13
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Drug resistance mutations detected by OLA, pyrosequencing and consensus sequencing at
baseline, and by OLA and consensus sequencing at virologic failure.
Note: Pre-ART specimens were tested by OLA (O), pyrosequencing (P), and consensus
sequencing (CS); virologic failure (VF) specimens were tested by OLA and CS only.
Numbers indicate the % mutant virus quantified by OLA (bold font, limit of detection = 2%)
or pyrosequencing (regular font, limit of detection 0.1%). Dark grey indicates mutation
detected by all methods evaluated. Light grey indicates mutation not detected by consensus
sequencing, except as indicated for subject #264. Numbers with no shading indicate
mutations detected by pyrosequencing only. NT = not tested (due to undetectable HIV viral
load). ind = indeterminate result by OLA due to the presence of different mutation. ^ =
mutation detected by OLA and consensus sequencing but not by pyrosequencing due to
sequence polymorphisms in the region of the pyrosequencing PCR primers.
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Figure 4.
Kaplan-Meier curve of time to virologic failure in participants grouped by whether or not
M184V, K103N, Y181C, and/or G190A was detected in baseline (pre-ART) viral
population, and if detected, the proportion of the mutant population: 0% (solid line), >0% to
<2% (short dashed line), and ≥2% (long dash line).
Note: The number of participants at risk at each time point is listed and the number
experiencing virologic failure is in parentheses.
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Table 1
Baseline comparison between those with and without transmitted drug resistance (TDR) detected by
oligonucleotide ligation assay (OLA) in pre-ART blood plasma.
Characteristic TDR (N=15) No TDR (N=371)
n (%) or Median (IQR) n (%) or Median (IQR) p-value
Age (years) 37 (32-43) 36 (30-42) 0.45
Female 9 (60) 246 (66) 0.59
Married or attached 7 (47) 192 (52) 0.80
Education (years) 11 (8-12) 12 (8-13) 0.19
Education 0.030 (overall)
    None 2 (13) 7 (2) 0.04
    Primary 4 (27) 124 (34) 0.78
    Secondary 8 (53) 144 (39) 0.29
    College 1 (7) 93 (25) 0.13
Employment 0.05 (overall)
    Salaried job 1 (7) 117 (32) 0.045
    Self-employed 4 (27) 82 (22) 0.75
    Casual laborer 5 (33) 49 (13) 0.045
    Unemployed 5 (33) 121 (33) 1.00
Rooms in house 2 (1-4) 2 (1-4) 0.76
Rent 2500 (570-7000) 2000 (1000-4500) 0.87
People in house 4 (1-6) 4 (2-5) 0.80
Flush toilet 8 (53) 173 (47) 0.79
Cost of travel to clinic ≥US$0.70 8 (53) 231 (62) 0.59
Distance to clinic (km) 9.5 (6.0-13.9) 10.3 (6.2-14.9) 0.64
Age at first sex (years) 17 (16-20) 18 (16-20) 0.76
Lifetime sexual partners 7 (4-10) 4 (2-6) 0.004
Money or favors for sex 3 (20) 35 (9) 0.18
Plasma HIV log10 copies/ml 5.85 (5.12-6.20) 5.67 (5.24-6.07) 0.70
CD4 count, cells/ml 100 (23-155) 116 (61-183) 0.29
Randomization assignment 0.18 (overall)
    Counseling 1 (7) 94 (25) 0.13
    Alarm 7 (47) 91 (25) 0.07
    Counseling and alarm 3 (20) 93 (25) 1.00
    Control 4 (27) 93 (25) 1.00
Median (IQR) is presented unless otherwise specified
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